{
    "address": "Kungsgatan 29",
    "city": "Stockholm",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W2R38N123",
    "description": "Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. The company is headquartered in Stockholm, Stockholm and currently employs 11 full-time employees. The company went IPO on 2013-05-20. The company is active in the field of pharmaceutical development and investments in stem cell and medical technology. The firm develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.",
    "employeeTotal": "11.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2013-05-20",
    "isin": "SE0005162880",
    "logo": "https://finnhub.io/api/logo?symbol=DMYD B.ST",
    "marketCapitalization": 2098.013,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Diamyd Medical AB",
    "phone": "4686610026.0",
    "sedol": "B849N98",
    "shareOutstanding": 71.569796,
    "state": "STOCKHOLM",
    "ticker": "DMYD B.ST",
    "weburl": "http://www.diamyd.com"
}